March 17, 2023
CVM issues Letter to Industry on GFI 256 phase-in
In response to a request from APC and NCPA, FDA’s Center for Veterinary Medicine last week issued a Letter to Industry explaining the phased-in approach to enforcement the agency plans to take on GFI 256.
“We’re grateful to CVM for this important communication,” said APC Board Chair Anthony Grzib. “In tandem with the answers to our technical questions CVM shared with us last month, it helps pharmacy compounders and state boards of pharmacy understand FDA’s thinking.”
